Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 180

The DOI matches its Crossref record.

Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment Week 96 Results

Open access
Wohl, David, Oka, Shinichi, Clumeck, Nathan, Clarke, Amanda, Brinson, Cynthia, Stephens, Jeffrey, Tashima, Karen, Arribas, Jose R., Rashbaum, Bruce, Cheret, Antoine, Brunetta, Jason, Mussini, Cristina, Tebas, Pablo, Sax, Paul E., Cheng, Andrew, Zhong, Lijie, Callebaut, Christian, Das, Moupali, Fordyce, Marshall · 2016 · JAIDS Journal of Acquired Immune Deficiency Syndromes

Abstract

In 2 double-blinded Phase 3 trials, 1733 antiretroviral-naive participants were randomized to tenofovir alafenamide (TAF), a tenofovir prodrug versus tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir/cobicistat/emtricitabine (E/C/F). At 96 weeks, 86.6% in the TAF arm and 85.2% in the TDF arm had HIV-1 RNA <50 c/mL [difference 1.5%; (95% CI: -1.8% to 4.8%)]. With TAF, there are smaller declines in bone mineral density and more favorable changes in proteinuria, albuminuria, and tubular proteinuria, and no cases of proximal tubulopathy compared with 2 for TDF. These longer-term data support E/C/F/TAF as a safe, well-tolerated, and durable regimen for initial HIV-1 treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/qai.0000000000000940

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 180

Metadata

Authors
Wohl, D., Oka, S., Clumeck, N., Clarke, A., Brinson, C., Stephens, J., Tashima, K., Arribas, J. R., Rashbaum, B., Cheret, A., Brunetta, J., Mussini, C., Tebas, P., Sax, P. E., Cheng, A., Zhong, L., Callebaut, C., Das, M., & Fordyce, M.
Venue
JAIDS Journal of Acquired Immune Deficiency Syndromes
Published
2016-05-01
Volume
72
Issue
1
Pages
58-64
ISSN
1525-4135 (ISSN-L)
OpenAlex
W2327535499
Cited by
180
References
0
FWCI
29.40
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment Week 96 Results. https://app.cochat.ai/papers/10.1097/qai.0000000000000940
The paper
Wohl, D., Oka, S., Clumeck, N., Clarke, A., Brinson, C., Stephens, J., Tashima, K., Arribas, J. R., Rashbaum, B., Cheret, A., Brunetta, J., Mussini, C., Tebas, P., Sax, P. E., Cheng, A., Zhong, L., Callebaut, C., Das, M., & Fordyce, M. (2016). Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment Week 96 Results. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/qai.0000000000000940

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.